{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/psoriasis/diagnosis/assessment/","result":{"pageContext":{"chapter":{"id":"067d150c-d6d4-5992-9319-f86bfeecca88","slug":"assessment","fullItemName":"Assessment","depth":2,"htmlHeader":"<!-- begin field 4169f641-133c-43b6-8533-c9d34842573d --><h2>How should I assess a person with suspected psoriasis?</h2><!-- end field 4169f641-133c-43b6-8533-c9d34842573d -->","summary":"","htmlStringContent":"<!-- begin item 0219a465-d9df-4460-b32b-508fefab425a --><!-- begin field ce6f9028-fe28-407d-b059-0d3e4bf2fb0e --><p><strong>If a diagnosis of psoriasis is suspected, assess the person's clinical features and consider whether there may be an </strong><a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/differential-diagnosis/\">alternative diagnosis</a><strong>.</strong></p><ul><li><strong>Ask about:</strong><ul><li>The sites and extent of involvement, to help <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/diagnosis/\">classify the type</a> of psoriasis, which will guide management.</li><li>Symptoms of skin involvement, such as itch, irritation, burning, pain, bleeding, and scaling.</li><li>Symptoms of systemic illness, such as fever, malaise, and weight loss, especially if medical emergencies such as <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/diagnosis/#pustular-psoriasis\">generalized pustular psoriasis</a> or <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/diagnosis/#erythrodermic-psoriasis\">erythrodermic psoriasis</a> are suspected.</li><li>Any known <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/background-information/trigger-factors/\">trigger factors</a> or any relationship to areas of trauma, suggesting the Koebner phenomenon.</li><li>Articular symptoms of unexplained joint stiffness, pain, or swelling; or nail changes, that may suggest a diagnosis of <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/background-information/associated-conditions/\">psoriatic arthritis</a>.<ul><li>Consider using the <a href=\"http://www.bad.org.uk/shared/get-file.ashx?id=1655&itemtype=document\" target=\"_blank\" data-hyperlink-id=\"b060a0a0-bb36-4cdf-827a-a93100a23290\">Psoriasis Epidemiology Screening Tool (PEST)</a> — if a person scores three or more out of five, consider arranging a referral to a rheumatologist.</li><li>Note: the PEST does not detect axial arthritis or inflammatory back pain.</li></ul></li><li><a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/background-information/associated-conditions/\">Associated conditions</a> such as inflammatory bowel disease or obesity.</li><li>Any treatments used, including over-the-counter preparations.</li><li>The person's perception of severity of psoriasis — consider using the 7-point Patient's Global Assessment (PGA) score with points indicating increasing severity: ranging from clear (scores 0); nearly clear; mild; moderate; severe; or very severe (6).</li><li>The physical, psychological, and social impact of psoriasis on the person's daily functioning and activities, including home, work, leisure, and/or impact on family or other dependents.<ul><li>Consider using the <a href=\"http://sites.cardiff.ac.uk/dermatology/files/2014/07/DLQI.pdf\" target=\"_blank\" data-hyperlink-id=\"475a4030-e4b5-45d9-a3bc-a93100a23299\">Dermatology Life Quality Index (DLQI) tool</a> to assess the impact of psoriasis.</li><li>Be aware that the degree of impact may not correlate with objective measures of disease extent or severity.</li></ul></li><li>Any associated stress, distress, anxiety and/or depression. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/generalized-anxiety-disorder/\">Generalized anxiety disorder</a> and <a class=\"topic-reference external-reference\" href=\"/topics/depression/\">Depression</a> for more information.</li><li>Any family history of psoriasis or psoriatic arthritis.</li></ul></li><li><strong>Assess the person's:</strong><ul><li>Cardiovascular risk — see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/\">CVD risk assessment and management</a> for more information.</li></ul></li><li><strong>Examine the person:</strong><ul><li>Assess for signs of systemic illness, such as fever or hypothermia, weight loss, dehydration, tachycardia, hypotension (may be seen in <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/diagnosis/#pustular-psoriasis\">generalized pustular psoriasis</a> or <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/diagnosis/#erythrodermic-psoriasis\">erythrodermic psoriasis</a>).</li><li>Assess skin lesions over the whole body, where possible, to <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/diagnosis/\">classify the type</a> of psoriasis:<ul><li>Distribution — psoriasis often occurs on extensor surfaces (elbows and knees), trunk, flexures, sacral and natal cleft, scalp and behind the ears, and umbilicus.</li><li>Size and shape of lesions — plaque psoriasis generally presents as large plaques, whereas guttate psoriasis presents as smaller 'droplet' lesions. There is usually a clear delineation between normal and affected skin.</li><li>Number of lesions — some people will have only a few lesions (for example chronic plaque psoriasis affecting only the extensor surfaces), but others will have many (for example, numerous small lesions of guttate psoriasis).</li><li>Severity of lesions — consider recording the severity of psoriasis using the 7-point Physician's Global Assessment (PGA) score with points indicating increasing severity: ranging from clear (scores 0); nearly clear; mild; moderate; severe; or very severe (6). Note: be aware that erythema may be under-estimated in people with pigmented skin types.</li><li>Surface features — whether smooth, scaly, or pustular.</li><li>Colour — may be pink or red, but in people with pigmented skin this may not be obvious. Scale is typically silvery in colour.</li><li>Involvement of other areas — such as signs of joint tenderness or swelling suggesting psoriatic arthritis, or <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/diagnosis/#nail-psoriasis\">nail changes</a>.</li></ul></li><li>Assess and document the proportion of total body surface area (BSA) affected by psoriasis, which can be estimated using the 'Rule of Nines' (traditionally used for burns assessment). For more information, see the <a href=\"http://frontlinefirstaid.ca/free-downloads/lund-and-browder-burn-chart-emr-bc-emalb.pdf\" target=\"_blank\" data-hyperlink-id=\"21cc0679-028d-4820-b9e3-a93100a232fc\">Lund and Browder chart (pdf)</a> for calculating the percentage of total body surface affected:<ul><li>Arm — 9%.</li><li>Head — 9%.</li><li>Neck — 1%.</li><li>Leg — 18%.</li><li>Anterior trunk — 18%.</li><li>Posterior trunk — 18%.</li><li>Note: estimating BSA involvement can be difficult, especially with small plaque or guttate psoriasis.</li></ul></li></ul></li></ul><!-- end field ce6f9028-fe28-407d-b059-0d3e4bf2fb0e --><!-- end item 0219a465-d9df-4460-b32b-508fefab425a -->","topic":{"id":"a3ecec3a-acde-5ece-90b0-dedc6c08db8b","topicId":"c8702cb0-6f30-44e4-832b-ab9161ee384a","topicName":"Psoriasis","slug":"psoriasis","lastRevised":"Last revised in December 2020","chapters":[{"id":"d0c39045-d8df-5a7e-bd7d-96fef3aefc3a","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"6e22adaa-de33-5d1c-bc1f-9740d238c5a2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a7c9da10-9760-5143-bf20-167f1e832103","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"409aaeee-7f7b-53cc-afdc-9ea9034984d6","slug":"changes","fullItemName":"Changes"},{"id":"1677a6dc-645a-58fe-8ed8-8bdfcface768","slug":"update","fullItemName":"Update"}]},{"id":"ca38cddf-4680-5dc4-a0df-79ab9910a789","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"fc350387-9e56-5f4b-b454-3cfa5ecd9a2a","slug":"goals","fullItemName":"Goals"},{"id":"00a9f2b3-e7b5-5394-9762-48d34a0dc722","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"400cbb71-cb76-5ee3-824a-738bc6249b3b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ad046045-038c-5b75-8f42-50343d5b824e","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"773d3740-99b6-5a32-b555-968b2efb0b8b","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0692cf2f-4b3d-5098-afe3-ac07b3c763ff","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d16fcd88-1021-5238-86e4-2452eee7fdde","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ef476810-392e-5b83-b527-fe921221cc0b","slug":"definition","fullItemName":"Definition"},{"id":"fb1e0af3-fd46-562a-83d6-33a31640b639","slug":"prevalence","fullItemName":"Prevalence"},{"id":"d6b8dab4-762f-5e9e-a83e-35a3652483b3","slug":"trigger-factors","fullItemName":"Trigger factors"},{"id":"70837c8d-73ae-5bc4-a042-949d31503ca3","slug":"associated-conditions","fullItemName":"Associated conditions"},{"id":"e90f3736-0e28-53fa-8295-309df8aa8e00","slug":"complications","fullItemName":"Complications"},{"id":"9523ad16-6e73-50ba-94bd-64c548f5c313","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4d0deda5-f89f-59e7-8978-1c3337afdcfe","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"067d150c-d6d4-5992-9319-f86bfeecca88","slug":"assessment","fullItemName":"Assessment"},{"id":"58b4da96-dda6-596b-9570-fd5070898cfe","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"27af05e5-54bf-5bc5-ba76-d1b8f18e7252","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"eaab9e94-c74e-5c84-ba14-d8db3a6dd1e8","fullItemName":"Management","slug":"management","subChapters":[{"id":"82ee7501-0589-54c2-8df7-5a9256a3f1d0","slug":"pustular-or-erythrodermic-psoriasis","fullItemName":"Scenario: Pustular or erythrodermic psoriasis"},{"id":"e4183760-c129-567e-9211-cef27ef68100","slug":"trunk-limbs","fullItemName":"Scenario: Trunk and limbs"},{"id":"6a7e9d56-0d17-5c90-b835-822367fbcd3e","slug":"scalp-psoriasis","fullItemName":"Scenario: Scalp psoriasis"},{"id":"9c7cebad-a77f-5fa8-811a-50815577a51c","slug":"facial-flexural/genital-psoriasis","fullItemName":"Scenario: Facial/flexural/genital psoriasis"},{"id":"6fbadcef-730e-5874-97ad-53e1f12bd5e3","slug":"guttate-psoriasis","fullItemName":"Scenario: Guttate psoriasis"},{"id":"a069495e-d2fe-5fca-9799-1b5f4f874033","slug":"nail-psoriasis","fullItemName":"Scenario: Nail psoriasis"},{"id":"08dc9427-b5ec-59f4-b47b-72a666beacef","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"ce3be64b-a968-59e2-b206-5a055de98330","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"520d3bb6-49cf-5f46-b761-9df1c712ad28","slug":"emollients","fullItemName":"Emollients"},{"id":"2a68bcd1-b92f-579a-955e-f4638d00073f","slug":"vitamin-d-preparations","fullItemName":"Vitamin D preparations"},{"id":"39f1a594-6e44-59b9-bb85-a277475d7386","slug":"salicylic-acid","fullItemName":"Salicylic acid"},{"id":"325d4c77-192a-5152-971f-a5f4f1d64fc7","slug":"coal-tar-products","fullItemName":"Coal tar products"},{"id":"302b90f5-e0d6-53cc-88ce-6a06def02b51","slug":"dithranol-short-contact","fullItemName":"Dithranol (short-contact)"}]},{"id":"00678b76-cc05-5d69-a6be-8760727fb9cf","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"91ae130b-06c7-538c-a295-af4bf7a3dbf1","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"358d84df-224b-5d6b-96cd-c52dfe00a200","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"383c93f2-ae1f-5c75-af43-3a9a448c1669","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3703e9fb-0103-5fe6-a0ed-192226578ed6","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d248a57f-2b73-5c2f-89c5-18ed618c3535","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e35fcef8-37a3-5afe-9250-f527d2c6e017","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"7314bc52-4cb9-530c-a905-917edad0de05","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"4d0deda5-f89f-59e7-8978-1c3337afdcfe","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"864bf502-8128-5749-81e1-ab8d9103583a","slug":"basis-for-recommendation-be9","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 4c68490d-5800-4ae8-8e5a-1455ea6c9090 --><h3>Basis for recommendation</h3><!-- end field 4c68490d-5800-4ae8-8e5a-1455ea6c9090 -->","summary":null,"htmlStringContent":"<!-- begin item be924a7d-6bd3-4727-b474-106c51fd3232 --><!-- begin field 6b54cfac-4447-4d11-9287-352b1c9754e9 --><p>The recommendations on assessment are based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Psoriasis: assessment and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">NICE, 2017</a>], the Scottish Intercollegiate Guidelines Network (SIGN) clinical guideline <em>Diagnosis and management of psoriasis and psoriatic arthritis in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">SIGN, 2010a</a>], a concise guideline on psoriasis convened by NICE in association with the Royal College of Physicians [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Samarasekera, 2014</a>], a systematic review on topical therapies for plaque psoriasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Samarasekera, 2013</a>], and expert opinion in review articles on psoriasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Cohen, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Johnson, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Weigle, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Boehncke, 2015</a>] and psoriatic arthropathy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Lenman, 2014</a>].</p><h4>Using the Psoriasis Epidemiology Screening Tool (PEST)</h4><ul><li>The recommendation on using the Psoriasis Epidemiology Screening Tool (PEST) is based on the NICE clinical guideline, which found it had good validity and was simple and easy to use [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">NICE, 2017</a>].<ul><li>A review article on psoriatic arthropathy in primary care cites a sensitivity of 0.92 and specificity of 0.78 for the PEST [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Lenman, 2014</a>].</li></ul></li></ul><h4>Assessing the severity and impact of psoriasis</h4><ul><li>The recommendation on using tools in primary care to assess disease severity and impact has been extrapolated from the NICE clinical guideline, as their use in specialist settings allows improved awareness of disease impact on the person, and monitoring of disease progression and treatment effectiveness [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">NICE, 2017</a>].<ul><li>The information that the impact of psoriasis on the person may not correlate with objective disease extent or severity is based on a systematic review of treatment for plaque psoriasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Samarasekera, 2013</a>].</li></ul></li></ul><h4>Asking about family history</h4><ul><li>The recommendation on asking about family history is based on the fact that population studies suggest a higher incidence of psoriasis in first-degree and second-degree relatives than in the general population, and concordance rates in monozygotic twins are up to three times higher than in dizygotic twins [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Boehncke, 2015</a>].<ul><li>This is supported by a US review article on psoriasis, which states that about one-third of people with psoriasis have a first-degree relative with the condition [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Weigle, 2013</a>].</li></ul></li></ul><h4>Assessing the body surface area (BSA)</h4><ul><li>The recommendation on assessing the BSA on examination is based on the NICE clinical guideline, which highlights the importance of getting a baseline measurement of the extent of psoriasis, to allow assessment of skin response following the start of treatment, and to prompt specialist dermatology referral if the BSA affected is more than 10% [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">NICE, 2017</a>].</li></ul><!-- end field 6b54cfac-4447-4d11-9287-352b1c9754e9 --><!-- end item be924a7d-6bd3-4727-b474-106c51fd3232 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}